Related by context. All words. (Click for frequent words.) 88 Phase II 83 Phase III clinical 81 pivotal Phase III 80 Phase IIb 78 phase IIa 78 Phase Ib 78 Phase 2b 77 phase IIb 77 Phase 77 Phase IIb trial 77 Phase 2b trial 76 Phase III trials 76 Phase 2a 76 Phase 1b 76 Phase IIa 76 Phase 2b study 76 Phase 2b clinical 76 phase IIa clinical 75 Phase 1a 75 Phase IIa clinical 74 Phase 2a clinical 74 Phase Ib clinical 74 Phase III clinical trials 74 Phase IIb clinical 73 Phase IIa trial 73 pivotal Phase 72 phase 2a 72 phase IIb clinical 72 Phase Ib II 72 Phase III pivotal 71 Phase IIB 71 Phase IIIb clinical 71 phase Ib 71 clinical trial 71 Phase 2a trial 71 Phase 1b clinical 70 Phase Ib study 70 Phase #b/#a 69 confirmatory Phase III 69 Phase Ia 69 Phase IIIb 68 registrational 68 Phase IIa trials 68 placebo controlled Phase 68 Phase 1b trial 68 dose escalation trial 68 randomized Phase 68 dose escalation Phase 68 multicenter Phase 67 Phase IIb trials 67 phase IIb trial 67 confirmatory Phase 3 67 clinical trials 67 APEX PD 67 GALNS 67 multicenter Phase II 66 Phase 2b clinical trials 66 randomized Phase IIb 66 BRIM3 66 multicenter randomized Phase 65 placebo controlled clinical 65 Amrubicin 65 phase Ib clinical 65 placebo controlled Phase III 65 randomized Phase III 65 Urocidin 65 placebo controlled 65 ENDEAVOR IV 65 Phase IIb clinical trials 64 multiple ascending dose 64 randomized controlled Phase 64 Phase III randomized controlled 64 Pivotal Phase III 64 registrational trial 64 BRIM2 64 SUCCEED trial 64 Zerenex 64 dose escalation study 64 Phase 1a clinical 64 ozarelix 64 NO# [002] 64 multicenter randomized placebo controlled 64 alvespimycin 64 IIa trial 63 Phase III psoriasis 63 cetrorelix 63 Pivotal Trial 63 ADVANCE PD 63 INCB# [001] 63 mipomersen 63 dose escalation clinical 63 Cloretazine R VNP#M 63 multicenter clinical 63 Phase III confirmatory 63 JAK inhibitor 63 pivotal bioequivalence 63 multicenter phase 63 multicenter Phase III 63 Phase Ib clinical trials 63 Phase III Clinical Trials 63 Phase III randomized 63 Phase III placebo controlled 63 EOquin 63 BCX# 63 Phase III Pivotal 62 Phase 2b kidney transplant 62 Corlux 62 multicentre randomized 62 Phase III Clinical Trial 62 dose escalation 62 MEND CABG 62 Phase Ib IIa 62 LibiGel Phase III 62 LUMINATE 62 phase IIb study 62 initiate Phase IIb 62 IIb clinical trial 62 initiate Phase 2b 62 Pivotal Phase 62 randomized Phase 2b 62 Phase #/#a 62 Phase #b/#a clinical 62 Phase IV 62 preclinical 62 GLP toxicology studies 62 Dacogen injection 62 Oglemilast 62 Initiate Phase 62 lintuzumab 62 TG MV 62 ITAX 62 AP# [003] 62 Zenvia Phase III 62 OvaRex ® MAb 62 oral ridaforolimus 62 bardoxolone 62 placebo controlled randomized 62 TMC# [002] 62 Elagolix 62 PREOS R 62 initiate Phase Ib 62 aclidinium bromide 62 Phase 1b dose escalation 61 PFO migraine 61 BLA filing 61 Mipomersen 61 ASA# 61 PEG PAL 61 double blinded placebo 61 confirmatory Phase 61 ILLUMINATE 61 Phenoptin 61 randomized placebo controlled 61 T DM1 61 dirucotide 61 HuMax EGFr 61 BLOOM DM 61 teduglutide 61 axitinib 61 ongoing Phase 1b 61 Phase IIb kidney transplant 61 initiate Phase 61 mertansine 61 Phase IIb III 61 EOquin TM 61 Phase III Trial 61 Asentar 61 Archexin 61 phase IIIb 61 Initiated Phase 61 phase IIb III 61 randomized double 61 Ozarelix 61 double blinded randomized 61 randomized controlled multicenter 61 deforolimus 61 Phase III HEAT 61 LUX Lung 61 elotuzumab 60 midstage trials 60 Alpharadin 60 confirmatory clinical 60 randomized controlled 60 PRX # 60 ularitide 60 XL# [003] 60 rALLy clinical trial 60 HuMax CD4 60 Aryplase 60 relapsed refractory multiple myeloma 60 COMFORT II 60 IIa trials 60 Fx #A 60 HuMax CD# 60 alvimopan 60 double blind placebo 60 Phase III registrational 60 Investigational Device Exemption IDE 60 Darusentan 60 R#/MEM # 60 Fodosine 60 Proxinium TM 60 TBC# 60 ToGA 60 opioid induced bowel dysfunction 60 pharmacokinetic PK study 60 lorcaserin Phase 60 dose cohort 60 investigational drug 60 SPIRIT III 60 ATL# [001] 60 IND submission 60 glufosfamide 60 tanespimycin 60 ANCHOR trial 60 ocrelizumab 60 randomized multicenter 60 TASKi2 60 KRN# 60 multicenter 60 tolevamer 60 Exherin TM 60 perifosine 60 Pirfenidone 60 trastuzumab DM1 60 Cloretazine ® 60 pharmacokinetic PK 60 SEPET TM 60 IMGN# 60 eculizumab 60 NP2 Enkephalin 60 PANVAC VF 60 multicenter randomized double 60 Augment Injectable 60 GetGoal Phase III 60 oral deforolimus 60 MOZOBIL 60 PREOS 60 FOLOTYN ® 60 SYMMETRY trial 60 IMPACT IMmunotherapy 60 LBH# 60 cannabinor 60 FORTIS M trial 60 single ascending dose 60 Pivotal Study 60 orBec 60 eltrombopag 60 IIa clinical 60 CLL8 60 L BLP# 60 Daclizumab 60 INCB# [002] 60 Aplidin 60 carfilzomib 60 Androxal TM 59 Anturol TM 59 IND enabling 59 phase III ACCLAIM 59 European Sepsis Trial 59 Phase IIA 59 Plicera 59 SNT MC# 59 clinical pharmacology studies 59 Phase IIb Trial 59 Zybrestat 59 Phase lll 59 CLIRS trial 59 forodesine 59 investigational compound 59 ruxolitinib 59 TMC# C# 59 omacetaxine mepesuccinate 59 IIa clinical trial 59 MIST II 59 metastatic hormone refractory 59 OLYMPIA registry 59 VEGF Trap 59 Phase IIa clinical trials 59 OvaRex R 59 reslizumab 59 Luveniq 59 Allovectin 7 59 dose cohorts 59 IMA# 59 OPT CHF 59 AIR CF2 59 unblind 59 Phase 2b monotherapy 59 blind randomized placebo 59 BLA submission 59 Phase 2a clinical trials 59 PRESEPT 59 blinded randomized placebo controlled 59 Vicriviroc 59 RSD# oral 59 AVADO 59 Laquinimod 59 methylnaltrexone 59 oral calcitonin 59 randomized clinical 59 assessing T DM1 59 riociguat 59 Zemplar Capsules 59 randomized multicenter Phase III 59 multicenter prospective 59 Maximum Tolerated Dose 59 ELACYT 59 randomized multicentre 59 neurogenic orthostatic hypotension 59 laquinimod 59 bicifadine 59 ThermoDox ® 59 ENDEAVOR III 59 Relovair 59 ThermoDox R 59 masked placebo controlled 59 TASQ 59 ABSORB trial 59 Phase 2b randomized 59 Prostate AdenoCarcinoma Treatment 59 oral treprostinil 59 PF # [002] 59 pharmacokinetic 59 blinatumomab 59 BAY #-# 59 sunitinib malate 59 Phase IIIb study 59 CLIRS 59 enzastaurin 59 Tarceva TM 59 budesonide MMX 59 fostamatinib 59 StemEx 59 multicenter randomized controlled 59 rALLy trial 59 Omnitarg 59 midstage clinical 58 TASKi3 58 seliciclib CYC# 58 PDE4 inhibitor 58 aclidinium 58 EchoCRT 58 IL# PE#QQR 58 Omigard 58 UPLYSO 58 severe hypercholesterolemia 58 AQ4N 58 ixabepilone 58 apaziquone 58 alogliptin 58 Phase III TRIST 58 Phase IIB clinical 58 tesmilifene 58 peginesatide 58 dexanabinol 58 pharmacokinetics PK 58 budesonide foam 58 Ambrisentan 58 daclizumab 58 sapacitabine 58 IMPACT DCM 58 NDA submission 58 diabetic neuropathic pain 58 Triolex 58 lomitapide 58 EFAPROXYN 58 dosing cohort 58 multicenter placebo controlled 58 BrachySil TM 58 baminercept 58 AZILECT R 58 Aclidinium 58 Phase III multicenter 58 Fibrillex TM 58 clofarabine 58 Flutiform ™ 58 YONDELIS 58 rNAPc2 58 Capesaris 58 darusentan 58 ascending dose 58 dexpramipexole 58 prospective multicenter randomized 58 OLpur TM H2H 58 Plenaxis TM 58 Pimavanserin 58 randomized controlled clinical 58 ofatumumab 58 Azedra 58 Amigal 58 elacytarabine 58 MGCD# [001] 58 Phases II 58 Alzhemed TM 58 Annamycin 58 Gabapentin GR 58 velafermin 58 PROPEL trial 58 pharmacodynamic PD 58 ZYBRESTAT 58 Phase III VISTA 58 MBP# [001] 58 CUSTOM III 58 elagolix 58 AeroLEF TM 58 Vectibix panitumumab 58 Acapodene 58 cangrelor 58 Ostarine 58 neratinib 58 Viramidine 58 MAA submission 58 Bronchitol 58 fidaxomicin Phase 3 58 IMC A# 58 Phase #b/#a trial 58 Clinical Trial 58 PXD# 58 lorvotuzumab mertansine 58 PMA submission 58 octreotide implant 58 Phase 1b clinical trials 58 prospective multicenter 58 PSMA ADC 58 Huntexil 58 Levacor 58 Randomized Phase 58 viral kinetic 58 PRIMO CABG 58 LibiGel ® 58 evaluating mipomersen 58 miconazole Lauriad ® 58 BST CarGel R 58 metastatic castrate resistant 58 docetaxel Taxotere R 58 isavuconazole 58 acyclovir Lauriad R 58 Phase IIa proof 58 Ocrelizumab 58 Dextofisopam 58 unblinding 58 Milnacipran 58 Phase 2b Clinical Trial 58 CEQ# 58 PSN# [002] 58 CRMD# 58 LymphoStat B 57 Dose Ranging Study 57 pharmacokinetic studies 57 huC# DM4 57 Glybera R 57 Allovectin 7 R 57 EndoTAG TM -1 57 lubiprostone 57 tamibarotene 57 STRIDE PD 57 trastuzumab emtansine T DM1 57 Aurexis 57 compound INCB# 57 obatoclax 57 initiate Phase 1b 57 CoFactor 57 Aflibercept 57 efficacy endpoint 57 LUVENIQ 57 Benlysta belimumab 57 tramiprosate Alzhemed TM 57 multicentre 57 Bicifadine 57 Viprinex TM 57 Allovectin 7 ® 57 RG# [001] 57 AZILECT ® 57 QLT# 57 IMC #B 57 FORTIS M 57 farletuzumab 57 Panzem R NCD 57 AZX# Phase 57 Medidur TM FA 57 BR.# 57 Firazyr 57 Traficet EN 57 CR# vcMMAE 57 OHR/AVR# 57 Multiple Ascending Dose 57 EVEREST II 57 generation PNP inhibitor 57 Solorel 57 Evoltra TM 57 Cloretazine 57 Clolar ® 57 Lupuzor 57 AEG# 57 selective androgen receptor modulator 57 Diamyd ® 57 ALSYMPCA 57 Memryte 57 StemEx R 57 Icatibant 57 HspE7 57 ALN VSP Phase 57 Restanza 57 APPRAISE 57 Kynapid 57 lumiliximab 57 SCH # 57 oral prodrug 57 LCP AtorFen 57 Phase Ib IIa clinical 57 Rescula 57 CAMMS# 57 AEGR 57 OncoGel 57 PD LID 57 refractory metastatic colorectal cancer 57 MAGE A3 ASCI 57 GEM OS1 57 pertuzumab 57 ISIS # 57 PRT# 57 Urocortin 2 57 midstage studies 57 velaglucerase alfa 57 MERLIN TIMI 57 torezolid phosphate 57 candidates Dyloject TM 57 sNDA submission 57 Feasibility Trial 57 celgosivir 57 dalbavancin 57 Onyx Pharma 57 cancer neuroendocrine tumor 57 ganetespib 57 blind randomized 57 MEND CABG II 57 GATTEX TM 57 DU #b 57 tremelimumab 57 RhuDex ® 57 Phase #/#a trial 57 TLK# 57 Rezular 57 VALOR trial 57 Pivotal Trials 57 ataluren 57 vidofludimus 57 arzoxifene 57 LibiGel testosterone gel 57 VICTOR E1 57 dirucotide MBP# 57 ENRICH trial 57 Nuvion 57 TELCYTA 57 controlled multicenter 57 PRE SURGE 57 aflibercept 57 Orazol 57 denufosol 57 Phase #/#a clinical 57 CHAMPION PCI 57 Zenvia ™ 57 thorough QT 57 TACI Ig 57 prospective randomized placebo 57 Biopharmaceuticals AG 57 HCV RESPOND 2 57 CB2 selective receptor agonist 57 ThGRF 57 blinded randomized 57 FDA Investigational Device 57 label multicenter 57 REOLYSIN ® 57 VNP#M 57 ROCKET AF 57 Troxatyl 57 relapsed multiple myeloma 57 PrevOnco 57 KNS # 57 ZYBRESTAT fosbretabulin 57 prospective randomized multicenter 57 novel histone deacetylase 57 II Clinical Trial 57 bortezomib Velcade 57 Sapacitabine 57 preclinical toxicology 57 avanafil 57 huN# DM1 57 multicentre randomized double 57 cathepsin K inhibitor 57 Civacir 57 almorexant 57 RSD# 57 ELND# 57 Drug Eluting Stent System 56 histone deacetylase HDAC inhibitor 56 Phase IIb Clinical Trial 56 ascending doses 56 vosaroxin 56 Vitaxin 56 Safinamide 56 Phase III Trials 56 edoxaban 56 StaphVAX 56 SPIRIT FIRST 56 ALKS 56 PDX pralatrexate 56 OncoVex 56 belinostat 56 PF # [001] 56 linaclotide 56 receptor tyrosine kinase inhibitor 56 RELOVAIR ™ 56 APTIVUS 56 AIR CF1 56 COSIRA trial 56 multicenter multinational 56 ofatumumab HuMax CD# 56 Oncoscience AG 56 Canvaxin 56 Zensana TM 56 trastuzumab DM1 T DM1 56 TroVax 56 Prodarsan 56 photoprotective drug 56 Preos 56 NVA# 56 apricitabine 56 preclinical efficacy 56 Hyphanox 56 rindopepimut 56 Successfully Completes Phase 56 GSK# [002] 56 SinuNase 56 Actemra 56 eniluracil 56 AeroLEF 56 PRECISE Trial 56 LymphoStat B TM 56 Carfilzomib 56 Efficacy Results 56 Ixempra 56 incyclinide 56 Denufosol 56 Northera 56 PEG Interferon lambda 56 Phase III ALLEGRO 56 confirmatory pivotal 56 PEARL SC 56 Dose escalation 56 OncoVEX GM CSF 56 RhuDex 56 teriflunomide 56 Desmoteplase 56 PrevOnco ™ 56 Evoltra 56 Gattex 56 REVIVE Diabetes 56 dyskinesia PD LID 56 BrachySil 56 pegloticase 56 initiated Phase Ib 56 refractory CLL 56 investigational humanized monoclonal antibody 56 Cetrorelix 56 Sulonex 56 ProLindac 56 relapsing multiple sclerosis 56 voreloxin 56 Serada 56 rilonacept 56 ZACTIMA 56 RSR# 56 afatinib 56 PLK1 SNALP 56 MADIT II 56 GAMMAGARD 56 HGS# 56 Febuxostat 56 IPLEX 56 RE LY ® 56 Ketotransdel 56 Pre RELAX AHF 56 Marqibo 56 LAF# 56 COU AA 56 fosbretabulin 56 HCV SPRINT 56 Quinamed 56 HCD# [002] 56 CIP ISOTRETINOIN 56 Pivotal Clinical Trial 56 Proellex TM 56 Initiate Phase II 56 DDP# 56 MIVI III 56 TOLAMBA 56 Tocosol Paclitaxel 56 New Drug Application 56 EDEMA3 56 ENGAGE AF TIMI 56 Clonicel 56 anticancer compound 56 Meets Primary Endpoint 56 Clolar 56 albiglutide 56 eprotirome 56 PROSTVAC TM 56 ADAGIO study 56 nonrandomized 56 lintuzumab SGN 56 evaluating tivozanib 56 dose escalation phase 56 CIP TRAMADOL ER 56 Silodosin 56 Prosaptide 56 RESTORE CLI trial 56 maribavir 56 oral formulation 56 Tanespimycin 56 Efficacy Trial 56 abiraterone acetate 56 Spiegelmer ® 56 Oxypurinol 56 AMR# 56 ABSORB clinical 56 tesetaxel 56 Virulizin 56 TG# [001] 56 maximally tolerated dose 56 NEBIDO 56 Apixaban 56 CDP# 56 Genz # 56 AZD# 56 Dyloject TM 56 AzaSite Plus 56 ceftaroline 56 nab paclitaxel 56 Pazopanib 56 ospemifene 56 Marketing Authorization Application 56 LEVADEX ™ 56 Avastin adjuvant 56 inhaled AAT 56 TEMSO 56 catheter occlusion 56 Iloperidone 56 Cimzia TM 56 valopicitabine 56 albinterferon alfa 2b 56 multicenter dose escalation 56 Ceflatonin R 56 rALLy 56 PIX# trial 56 OvaRex 56 ANTEGREN 56 NUVIGIL 56 iniparib 55 Degarelix 55 Dapagliflozin 55 romidepsin 55 vilazodone 55 satraplatin Phase 55 dependent kinase inhibitor 55 Hematide 55 ZoMaxx 55 ORMD 55 Investigational 55 RDEA# 55 vemurafenib 55 Clinical Trial Results 55 investigational protease inhibitor 55 PHX# 55 Erbitux cetuximab 55 enoximone capsules 55 investigational 55 phase 55 registrational studies 55 cutaneous T cell 55 Lu AA# 55 vascular disrupting agent 55 canagliflozin 55 balsalazide tablet 55 Saforis 55 Stedivaze 55 ALD# 55 Diabetic Macular Edema 55 denosumab oncology 55 Tyrima 55 multicenter randomized 55 Achieves Primary Endpoint 55 MAP# 55 BioNumerik 55 prospective randomized 55 unblinded 55 GVAX 55 visilizumab 55 ACCEDE 55 PEP# [003] 55 ACTEMRA TM 55 picoplatin 55 R#/MEM 55 Ophena TM 55 generation purine nucleoside 55 MIRCERA 55 ONTARGET R 55 oral methylnaltrexone 55 Pafuramidine 55 Loramyc R 55 Alocrest 55 UVIDEM 55 NGX# 55 MAXY alpha 55 Sorafenib HCC Assessment 55 IND Investigational New 55 XIENCE V Stent System 55 labial herpes 55 solanezumab 55 initiate Phase IIa 55 Phase III Psoriasis 55 Voraxaze 55 CA4P 55 dosing cohorts 55 CCX# 55 cetuximab Erbitux 55 Reverset 55 MabThera rituximab 55 FlutiformTM 55 REG2 55 mg/m2 cohort 55 dextromethorphan quinidine 55 label dose escalation 55 BAL# [002] 55 tivozanib 55 Telaprevir 55 investigational pan BCR 55 ATTRACT 55 clinical trials Multikine 55 refractory AML 55 antibody MAb 55 oral taxane 55 telaprevir dosing 55 GLPG# 55 ILUVIEN ® 55 Antegren 55 trodusquemine 55 tezampanel 55 subcutaneous formulation 55 oxypurinol 55 Dacogen 55 pafuramidine 55 pradefovir 55 ACCLAIM II 55 Biologics License Application BLA 55 HGS ETR1 55 PS# [001] 55 Phase III ThermoDox 55 LEP ETU 55 nalbuphine ER 55 miconazole Lauriad R 55 Targretin 55 paclitaxel poliglumex 55 TKB# 55 PI3K/Akt pathway inhibitor 55 dimebon 55 Kahalalide F 55 EGS# 55 HoFH 55 Initiates Phase II 55 Perifosine 55 VITAL Trial 55 pomalidomide 55 olaparib 55 amrubicin 55 ZYBRESTAT TM 55 Vicinium TM 55 Vilazodone 55 midstage clinical trials 55 microplasmin 55 MDV# 55 active comparator 55 urocortin 2 55 LEVADEX 55 ONTARGET 55 mapatumumab 55 investigational antiplatelet agent 55 Ceflatonin 55 ambrisentan 55 6R BH4 55 pharmacodynamic effects 55 Zenvia TM 55 hypoxia activated prodrug 55 afamelanotide 55 Clevudine 55 GRN# 55 blinded placebo controlled 55 Iluvien TM 55 SPIRIT IV 55 Sym# 55 LibiGel 55 TM Drug Eluting 55 satraplatin 55 alemtuzumab Campath 55 Tesetaxel 55 Catena ® 55 PRIMO CABG2 55 QNEXA 55 Marketing Authorization Application MAA 55 Trofex 55 talactoferrin 55 EINSTEIN DVT 55 PREGNANT Study 55 pralatrexate 55 bendamustine 55 Onconase 55 crofelemer 55 selectin antagonist 55 subcutaneously administered 55 OMAPRO 55 CVac 55 atrasentan 55 ASCEND HF 55 ENDEAVOR II 55 CONSERV 55 subcutaneous Herceptin 55 Entereg 55 DEB# 55 prospective randomized controlled 55 nonclinical studies 55 TAXUS Element Stent System 55 brivaracetam 55 ICA # 55 regorafenib 55 tiapamil 55 Ereska 55 galiximab 55 Torisel 55 tezampanel NGX# 55 Androxal 55 HDAC Inhibitor 55 DSMB recommended 55 preclinical pharmacokinetic 55 MVax 55 SAR# [004] 55 Panzem R 55 Telcyta 55 eosinophilic asthma 55 RHUCIN 55 IDX# 55 Prestara 55 treatment naive genotype 55 Nexavar 55 Harry Palmin President 55 TAXUS ATLAS 55 PTH analogue 55 Ventavis 55 BRAF inhibitor 55 FOLOTYN 55 oral cladribine 55 DSMB 55 PRECISE trial 55 Viprinex 55 Trobalt 55 AIR CF3 55 Virulizin R 55 Trastuzumab DM1 55 DR Cysteamine 55 Onrigin 55 Randomized Phase II 55 Cimzia ® certolizumab pegol 55 Telatinib 55 metastatic sarcomas 55 Testosterone MDTS ® 55 blind multicenter 55 Pivotal Phase II 55 SinuNase TM 55 Zerenex ™ 55 HIV integrase inhibitor 55 Myocet 55 randomized discontinuation trial 55 RE LY 55 confirmatory 55 Combination REOLYSIN R 55 RE COVER 55 Onalta ™ 55 bapineuzumab 55 dose dose escalation 55 ORACLE MS 55 cediranib 55 Initiates Phase III 55 APEX AMI trial 55 Pemetrexed 55 PEG SN# 55 Factor VIIa 55 desvenlafaxine 55 Randomized Evaluation 55 Special Protocol Assessment